GlaxoSmithKline

US · GSK #177 by market cap Listed 1970 -1.82%

49.80 -0.93 -1.82%

Live - 304 symbols - heartbeat 533s ago · 2026-09-23 15:50

Pre-market 50.22 -0.99%

After-hours 50.72 0.00%

Overnight 50.28 -0.87%

Market cap: 99.76B
P/E (TTM): 15.84
P/B: 4.24
EPS: 3.71
Div yield: 3.56%
52W pos: 51%

Reader sentiment Are you bullish or bearish on GSK?

Anonymous reader poll. Unscientific, not investment advice.

Revenue annual, last 8 years

Latest year +4.11% YoY

Margins

Gross margin: 72.40%
Operating margin: 25.52%
Net margin: 17.50%

Key ratios & quality

Enterprise value: 113.63B
Altman Z-Score: 2.47

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

✦ Quant Financial Health how this is computed

Fair

Altman Z-Score is 2.47, in the 1.8-3.0 "grey zone".
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	30.82B	33.75B	24.35B	24.70B	29.32B	30.33B	31.38B	32.67B
Gross profit	20.58B	21.89B	16.43B	16.53B	19.77B	21.76B	22.33B	23.65B
Selling & admin expenses	9.92B	11.40B	7.44B	7.07B	8.37B	9.39B	11.02B	9.09B
Research & development	3.89B	4.57B	4.79B	5.02B	5.49B	6.22B	6.40B	7.53B
Operating profit	7.06B	6.29B	4.58B	4.88B	6.73B	7.35B	5.54B	8.34B
Pretax profit	4.80B	6.22B	5.17B	3.60B	5.63B	6.06B	3.48B	7.40B
Tax	754.00M	953.00M	67.00M	83.00M	707.00M	756.00M	526.00M	1.11B
Net profit	4.05B	5.27B	6.39B	5.10B	15.62B	5.31B	2.95B	6.29B
Basic EPS	2	2	3	2	7	2	1	3
Diluted EPS	1.82	2.32	2.85	2.16	7.32	2.40	1.24	2.78

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	7.52B	7.99B	8.55B	8.62B	7.63B	8.41B
Gross profit	5.58B	5.82B	6.29B	5.96B	5.75B	6.14B
Selling & admin expenses	2.07B	2.14B	2.24B	2.64B	2.12B	2.20B
Research & development	1.46B	2.02B	1.69B	2.35B	1.69B	3.47B
Operating profit	2.22B	2.02B	2.59B	1.51B	2.29B	481.00M
Pretax profit	2.11B	1.89B	2.46B	950.00M	2.14B	354.00M
Tax	336.00M	241.00M	312.00M	223.00M	305.00M	-199.00M
Net profit	1.77B	1.65B	2.14B	727.00M	1.84B	553.00M
Basic EPS	1	1	1	0	1	0
Diluted EPS	0.79	0.70	0.98	0.31	0.85	0.21

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	16.93B	19.49B	20.25B	18.67B	20.77B	18.64B	17.00B	17.51B
Cash & ST investments	3.96B	4.59B	6.17B	4.14B	7.68B	4.99B	3.71B	3.16B
Inventory	5.48B	5.95B	6.00B	5.78B	5.15B	5.50B	5.67B	5.92B
Total assets	58.07B	79.69B	80.43B	79.10B	60.15B	59.01B	59.46B	61.12B
Total current liabilities	22.49B	24.05B	22.15B	23.67B	22.81B	21.07B	21.70B	21.39B
Short-term debt	5.79B	6.92B	3.73B	3.60B	3.95B	2.81B	2.35B	3.01B
Long-term debt	20.23B	22.58B	22.54B	19.76B	16.19B	14.15B	13.70B	14.02B
Total liabilities	54,394,000,000.00	61,335,000,000.00	59,623,000,000.00	57,761,000,000.00	50,050,000,000.00	46,210,000,000.00	46,377,000,000.00	45,162,000,000.00
Total equity	3.67B	18.36B	20.81B	21.34B	10.10B	12.80B	13.09B	15.96B
Retained earnings	-2.72B	4.53B	6.76B	7.94B	4.36B	7.24B	7.80B	10.21B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	18.09B	17.67B	17.84B	17.51B	17.76B	17.56B
Cash & ST investments	4.49B	3.62B	3.31B	3.16B	3.44B	3.11B
Inventory	6.00B	6.07B	6.12B	5.92B	6.16B	6.28B
Total assets	60.71B	59.26B	61.34B	61.12B	62.87B	61.74B
Total current liabilities	20.83B	20.38B	21.33B	21.39B	22.43B	21.53B
Short-term debt	1.96B	2.05B	2.86B	3.01B	5.04B	4.29B
Long-term debt	--	--	--	14.02B	--	--
Total liabilities	47,051,000,000.00	44,904,000,000.00	45,587,000,000.00	45,162,000,000.00	45,447,000,000.00	44,561,000,000.00
Total equity	13.65B	14.35B	15.75B	15.96B	17.42B	17.18B
Retained earnings	8.31B	8.80B	10.02B	10.21B	11.59B	11.46B

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	8.42B	8.02B	8.44B	7.95B	7.40B	6.77B	6.55B	7.74B
Depreciation & amortization	--	--	--	--	--	--	--	--
Free cash flow	6.63B	5.86B	6.50B	5.30B	5.15B	4.42B	3.57B	4.76B
Dividends paid	-3.93B	-3.95B	-3.98B	-4.00B	-3.47B	-2.25B	-2.44B	-2.56B
Stock buybacks / issuance	74.00M	51.00M	29.00M	21.00M	25.00M	10.00M	20.00M	-1.36B
Ending cash balance	4.09B	4.83B	5.26B	3.82B	3.43B	2.86B	3.40B	3.21B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	1.15B	2.10B	2.22B	2.28B	1.14B	2.69B
Depreciation & amortization	--	--	--	--	--	--
Free cash flow	697.00M	1.46B	1.34B	1.25B	698.00M	2.04B
Dividends paid	-612.00M	-656.00M	-650.00M	-646.00M	-643.00M	-727.00M
Stock buybacks / issuance	-235.00M	-559.00M	-317.00M	-251.00M	-318.00M	-307.00M
Ending cash balance	4.25B	3.32B	2.76B	3.21B	3.20B	2.94B

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	168.83	58.93	44.24	29.59	116.60	41.16	19.06	38.05
ROA %	6.33	6.74	7.18	5.50	21.48	8.27	4.35	9.48
ROIC %	18.01	14.92	15.56	12.57	44.20	17.54	9.89	19.31
5-year avg ROE %	148.63	151.07	123.99	124.06	89.35	58.55	50.13	48.89
EBIT margin %	18.08	21.05	22.95	18.23	22.01	22.39	13.12	24.76
FCF / sales %	21.50	17.35	18.19	14.72	17.55	14.59	11.38	14.56
Current ratio	0.75	0.81	0.91	0.79	0.91	0.88	0.78	0.82
Quick ratio	0.45	0.48	0.58	0.49	0.61	0.54	0.45	0.46
Debt / assets	689.34	267.50	186.12	160.56	198.03	135.00	124.25	108.20
LT debt / equity	536.13	206.84	160.59	136.65	160.74	113.92	107.07	89.81
Interest coverage	7.23	8.03	9.14	8.00	7.81	9.36	6.43	11.77
Revenue CAGR (3Y) %	8.81	6.57	-6.91	-7.12	-4.58	7.59	8.31	3.66
Net income CAGR (3Y) %	-24.51	72.05	55.40	6.57	47.66	-5.01	-16.26	-27.43
FCF CAGR (3Y) %	114.85	12.21	11.26	-7.18	-4.23	-12.02	-12.31	-2.59

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	22.52	23.48	36.44	38.05	36.42	29.73
ROA %	5.29	5.84	9.20	9.48	9.43	7.97
ROIC %	11.31	12.25	18.68	19.31	18.42	15.90
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	15.43	16.65	23.85	24.76	24.80	19.86
FCF / sales %	12.29	14.75	14.60	14.56	14.51	16.06
Current ratio	0.87	0.87	0.84	0.82	0.79	0.82
Quick ratio	0.55	0.54	0.53	0.46	0.50	0.50
Debt / assets	130.20	117.33	109.92	108.20	106.74	103.36
LT debt / equity	116.37	103.47	92.23	89.81	78.49	79.04
Interest coverage	7.65	8.15	11.68	11.77	11.75	9.56
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

Revenue breakdown most recent period

Business

Commercial Operations100.00%

Quote time 2026-09-23 15:50:01 · For reference only, not investment advice.